Inhibition of IGF-1R in adrenocortical carcinoma
Mené sur 139 patients atteints d'un carcinome corticosurrénalien de stade localement avancé ou métastatique, cet essai randomisé international de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité du linsitinib
Adrenocortical carcinoma is a rare tumour, with an incidence around one per million. With the widespread availability of CT scanning, more tumours are being detected at earlier stages in their course; however, even in the current environment the median size of an adrenocortical carcinoma is still longer than 10 cm, and more than two-thirds of patients present with locally advanced or metastatic disease. The prognosis for patients with unresectable disease remains very poor, with the best available cytotoxic chemotherapy only leading to a quarter of patients achieving a response and median overall survival of less than 15 months.
The Lancet Oncology , commentaire, 2014